Home » Stocks » ADXN

Addex Therapeutics Ltd. (ADXN)

Stock Price: $9.30 USD -0.31 (-3.23%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 67.54M
Revenue (ttm) 3.78M
Net Income (ttm) -11.91M
Shares Out 7.26M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $9.30
Previous Close $9.61
Change ($) -0.31
Change (%) -3.23%
Day's Open 9.78
Day's Range 9.30 - 9.78
Day's Volume 1,990
52-Week Range 8.01 - 37.52


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.

1 week ago - Zacks Investment Research

Ge neva, Switzerland, May 5 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, tod...

2 months ago - GlobeNewsWire

KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today th...

5 months ago - Business Wire

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...

Other stocks mentioned: OBLN, GENE
6 months ago - Benzinga

Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is...

6 months ago - InvestorPlace

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...

6 months ago - GlobeNewsWire

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col... [Read more...]

Pharmaceutical Preparation Manufacturing
Tim Dyer
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, ADXN's revenue was 3.61 million, an increase of 30.77% compared to the previous year's 2.76 million. Losses were -12.86 million, -13.00% less than in 2019.

Financial numbers in millions CHF.
Financial Statements